MaxCyte is a life sciences tools company that sells instruments and consumables used to engineer living cells, primarily for developing and manufacturing cell therapies. Its core product is the ExPERT platform, a family of electroporation instruments that use electric fields to temporarily open cell membranes, allowing researchers and manufacturers to introduce genetic material — such as CRISPR components, mRNA, or DNA — into cells. The platform scales from small research applications to large clinical manufacturing runs. Alongside instruments, MaxCyte sells proprietary single-use Processing Assemblies (disposable fluid handling components) and buffer solution, both of which customers must repurchase for every run. MaxCyte's business model has two revenue streams: a recurring core business of instrument sales, annual per-instrument license fees, and consumable PA sales; and a long-term royalty-like stream tied to customer drug commercialization. Customers developing clinical-stage cell therapies sign Strategic Platform License (SPL) agreements, committing to milestone payments tied to clinical development events and post-approval royalties on any commercialized drugs. MaxCyte had 31 active SPL agreements as of end of 2025. CASGEVY, a gene therapy from Vertex and CRISPR Therapeutics approved for sickle cell disease, is MaxCyte's first commercial-stage SPL program. In January 2025, MaxCyte acquired SeQure Dx, which offers gene editing safety assessment services increasingly required by the FDA. MaxCyte sells directly in North America, the UK, and much of Europe, and uses distributors elsewhere, with a global installed base of 857 instruments.